Your session is about to expire
← Back to Search
Study Summary
This trialtests a new drug to treat Essential Thrombocythemia in adults, to see if it is safe, effective and well-tolerated.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My liver is functioning well according to recent tests.I am not allergic to IFN-α or its ingredients.I haven't had treatment to reduce my blood cell counts, or I've only had hydroxyurea and/or anagrelide.I agree to use birth control during and up to 60 days after the study, and I won't breastfeed if participating.I have or have not been treated with ANA before, regardless of why I stopped.I agree to use birth control during and for 60 days after the study, and I won't breastfeed if participating.I need someone legally authorized to make decisions for me.I stopped taking interferon alfa because it didn't work well or had bad side effects.My condition is officially diagnosed as Essential Thrombocythemia.My kidneys are working well enough (creatinine clearance ≥40 mL/min).I have been diagnosed with Essential Thrombocythemia according to WHO standards.I have had a major organ transplant.I am 18 years old or older.My liver tests are within normal ranges.I am 18 years old or older.I have never been treated with interferon.
- Group 1: Ropeginterferon alfa-2b (P1101)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the Food and Drug Administration authorized Ropeginterferon alfa-2b (P1101) for use?
"The safety of Ropeginterferon alfa-2b (P1101) was assessed to be a 2 as this is Phase 2 trial and data has been collected supporting its security, yet no clinical trials have proven it's effectiveness."
What is the current sample size of this clinical experiment?
"Affirmative. According to clinicaltrials.gov, this medical research is currently recruiting individuals; the experiment was initially posted on September 29th 2022 and modified just recently in November 9th 2022. In total 64 participants are needed from 23 sites."
Is enrollment for this trial currently open to participants?
"According to clinicaltrials.gov, this research is still enrolling participants and has been since it was published on September 29th 2022. Its most recent modification was observed November 9th 2021."
How many venues are actively conducting this research endeavor?
"This clinical trial is taking place at the University of Tennessee Health Science Centre in Memphis, Weill Medical College of Cornell University in New york and Juravinski Cancer Centre in Hamilton. In addition to these sites there are 20 other locations running this study."
Who else is applying?
What state do they live in?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger